 Ana Gleisner
Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 21 | 2023 | 722 | 3.810 |
Why?
| | Sentinel Lymph Node | 8 | 2022 | 38 | 3.000 |
Why?
| | Adenocarcinoma | 20 | 2023 | 799 | 2.760 |
Why?
| | Liver Neoplasms | 21 | 2024 | 521 | 2.730 |
Why?
| | Melanoma | 11 | 2022 | 651 | 2.600 |
Why?
| | Laparoscopy | 8 | 2021 | 400 | 2.570 |
Why?
| | Skin Neoplasms | 11 | 2022 | 761 | 2.470 |
Why?
| | Pancreaticoduodenectomy | 10 | 2021 | 130 | 2.360 |
Why?
| | Carcinoma, Hepatocellular | 9 | 2024 | 224 | 2.030 |
Why?
| | Lymph Node Excision | 10 | 2023 | 141 | 2.000 |
Why?
| | Pancreatectomy | 6 | 2023 | 169 | 1.890 |
Why?
| | Sentinel Lymph Node Biopsy | 11 | 2023 | 98 | 1.640 |
Why?
| | Hepatectomy | 17 | 2024 | 137 | 1.540 |
Why?
| | Minimally Invasive Surgical Procedures | 5 | 2020 | 154 | 1.360 |
Why?
| | Postoperative Complications | 11 | 2023 | 2161 | 1.240 |
Why?
| | Liver Transplantation | 10 | 2023 | 830 | 1.000 |
Why?
| | Esophagectomy | 4 | 2021 | 111 | 0.990 |
Why?
| | Lymph Nodes | 7 | 2023 | 423 | 0.980 |
Why?
| | Robotic Surgical Procedures | 3 | 2019 | 88 | 0.920 |
Why?
| | Retrospective Studies | 51 | 2024 | 12608 | 0.920 |
Why?
| | Esophageal Neoplasms | 7 | 2023 | 273 | 0.920 |
Why?
| | Conversion to Open Surgery | 2 | 2020 | 13 | 0.870 |
Why?
| | Nomograms | 2 | 2022 | 42 | 0.860 |
Why?
| | Carcinoma, Pancreatic Ductal | 5 | 2023 | 208 | 0.850 |
Why?
| | Breast Neoplasms | 4 | 2023 | 1872 | 0.810 |
Why?
| | Survival Rate | 22 | 2023 | 1650 | 0.800 |
Why?
| | Rectal Neoplasms | 5 | 2023 | 122 | 0.780 |
Why?
| | Lymphatic Metastasis | 10 | 2023 | 276 | 0.780 |
Why?
| | Prognosis | 24 | 2024 | 3339 | 0.740 |
Why?
| | Aged | 45 | 2023 | 19251 | 0.680 |
Why?
| | Quality of Life | 2 | 2019 | 2385 | 0.630 |
Why?
| | Middle Aged | 54 | 2023 | 26999 | 0.630 |
Why?
| | Neoplasm Recurrence, Local | 10 | 2023 | 863 | 0.620 |
Why?
| | Head and Neck Neoplasms | 6 | 2019 | 425 | 0.610 |
Why?
| | Humans | 92 | 2024 | 115587 | 0.600 |
Why?
| | Colorectal Neoplasms | 7 | 2017 | 617 | 0.560 |
Why?
| | Neoadjuvant Therapy | 11 | 2023 | 301 | 0.560 |
Why?
| | Neoplasm Staging | 10 | 2023 | 1178 | 0.540 |
Why?
| | Female | 65 | 2023 | 59913 | 0.530 |
Why?
| | Colectomy | 3 | 2013 | 87 | 0.520 |
Why?
| | Liver Failure | 3 | 2009 | 84 | 0.490 |
Why?
| | Male | 61 | 2023 | 55949 | 0.480 |
Why?
| | Colonic Neoplasms | 2 | 2013 | 222 | 0.450 |
Why?
| | Risk Assessment | 5 | 2019 | 2987 | 0.450 |
Why?
| | Axilla | 3 | 2023 | 39 | 0.440 |
Why?
| | Decision Making | 1 | 2019 | 791 | 0.430 |
Why?
| | Follow-Up Studies | 13 | 2021 | 4440 | 0.430 |
Why?
| | Treatment Outcome | 19 | 2023 | 9159 | 0.410 |
Why?
| | Databases, Factual | 6 | 2019 | 1138 | 0.350 |
Why?
| | Neuroendocrine Tumors | 2 | 2023 | 83 | 0.340 |
Why?
| | Benchmarking | 2 | 2021 | 163 | 0.330 |
Why?
| | Aged, 80 and over | 15 | 2021 | 6417 | 0.330 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 2 | 2019 | 11 | 0.330 |
Why?
| | Metastasectomy | 2 | 2023 | 12 | 0.330 |
Why?
| | Peritoneal Neoplasms | 2 | 2020 | 54 | 0.320 |
Why?
| | Margins of Excision | 4 | 2023 | 29 | 0.310 |
Why?
| | Propensity Score | 2 | 2019 | 225 | 0.310 |
Why?
| | Length of Stay | 4 | 2019 | 958 | 0.300 |
Why?
| | Mastectomy, Segmental | 2 | 2017 | 76 | 0.290 |
Why?
| | Disease-Free Survival | 8 | 2024 | 621 | 0.280 |
Why?
| | Catheter Ablation | 2 | 2008 | 291 | 0.270 |
Why?
| | Hyperglycemia | 2 | 2020 | 294 | 0.260 |
Why?
| | Adult | 28 | 2022 | 30718 | 0.250 |
Why?
| | Cohort Studies | 10 | 2023 | 4944 | 0.240 |
Why?
| | Abdomen, Acute | 1 | 2004 | 17 | 0.240 |
Why?
| | Bacterial Infections | 3 | 2006 | 222 | 0.230 |
Why?
| | Liver Cirrhosis | 3 | 2023 | 238 | 0.230 |
Why?
| | Lymphopenia | 1 | 2024 | 50 | 0.230 |
Why?
| | United States | 14 | 2023 | 12295 | 0.220 |
Why?
| | SEER Program | 2 | 2014 | 195 | 0.220 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 12 | 0.220 |
Why?
| | Survival Analysis | 6 | 2017 | 1219 | 0.210 |
Why?
| | Lung Neoplasms | 3 | 2023 | 2207 | 0.210 |
Why?
| | Mastectomy | 1 | 2023 | 99 | 0.210 |
Why?
| | Lymphoscintigraphy | 2 | 2019 | 9 | 0.210 |
Why?
| | Surgical Oncology | 1 | 2022 | 18 | 0.210 |
Why?
| | Pelvic Exenteration | 2 | 2019 | 11 | 0.200 |
Why?
| | Klatskin Tumor | 1 | 2021 | 4 | 0.200 |
Why?
| | Anesthetics, Inhalation | 1 | 2021 | 14 | 0.190 |
Why?
| | Cytoreduction Surgical Procedures | 2 | 2020 | 40 | 0.190 |
Why?
| | Bile Duct Neoplasms | 1 | 2021 | 56 | 0.190 |
Why?
| | Prospective Studies | 8 | 2022 | 6264 | 0.190 |
Why?
| | Propofol | 1 | 2021 | 43 | 0.190 |
Why?
| | Hyperthermia, Induced | 2 | 2020 | 65 | 0.190 |
Why?
| | Chemoradiotherapy | 4 | 2023 | 187 | 0.190 |
Why?
| | Organ Preservation | 4 | 2023 | 68 | 0.180 |
Why?
| | Odds Ratio | 3 | 2019 | 962 | 0.180 |
Why?
| | Registries | 2 | 2021 | 1770 | 0.180 |
Why?
| | Combined Modality Therapy | 5 | 2019 | 1127 | 0.170 |
Why?
| | Reoperation | 3 | 2017 | 525 | 0.170 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2023 | 334 | 0.170 |
Why?
| | Scalp | 1 | 2019 | 29 | 0.170 |
Why?
| | Anesthesia | 1 | 2021 | 119 | 0.170 |
Why?
| | Regression Analysis | 2 | 2019 | 959 | 0.160 |
Why?
| | Pancreatic Diseases | 1 | 2019 | 64 | 0.160 |
Why?
| | Skin Pigmentation | 1 | 2019 | 39 | 0.160 |
Why?
| | Neoplasms | 2 | 2022 | 2118 | 0.160 |
Why?
| | Population Surveillance | 1 | 2021 | 395 | 0.150 |
Why?
| | Appendiceal Neoplasms | 1 | 2017 | 14 | 0.150 |
Why?
| | Tumor Burden | 3 | 2023 | 261 | 0.150 |
Why?
| | Patient Reported Outcome Measures | 1 | 2019 | 250 | 0.150 |
Why?
| | Patient Compliance | 1 | 2021 | 524 | 0.150 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2017 | 23 | 0.150 |
Why?
| | Ampulla of Vater | 1 | 2017 | 29 | 0.140 |
Why?
| | Waiting Lists | 2 | 2009 | 223 | 0.140 |
Why?
| | Gastric Outlet Obstruction | 1 | 2017 | 7 | 0.140 |
Why?
| | Pylorus | 1 | 2017 | 11 | 0.140 |
Why?
| | Disease Management | 1 | 2021 | 563 | 0.140 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2017 | 76 | 0.140 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 123 | 0.140 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 39 | 0.140 |
Why?
| | Nutritional Status | 1 | 2019 | 289 | 0.140 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 30 | 0.140 |
Why?
| | Genital Neoplasms, Female | 1 | 2017 | 73 | 0.140 |
Why?
| | Neuromuscular Agents | 1 | 2017 | 30 | 0.140 |
Why?
| | Cannabis | 1 | 2023 | 381 | 0.140 |
Why?
| | Hospitals | 1 | 2021 | 585 | 0.140 |
Why?
| | Botulinum Toxins, Type A | 1 | 2017 | 40 | 0.130 |
Why?
| | Time Factors | 4 | 2021 | 6165 | 0.130 |
Why?
| | Proportional Hazards Models | 2 | 2022 | 1087 | 0.130 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 100 | 0.130 |
Why?
| | Adenoma | 1 | 2017 | 187 | 0.130 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 963 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 2 | 2016 | 2392 | 0.130 |
Why?
| | Radiosurgery | 1 | 2018 | 298 | 0.120 |
Why?
| | Anti-Bacterial Agents | 1 | 2004 | 1484 | 0.120 |
Why?
| | Antineoplastic Agents | 3 | 2021 | 1893 | 0.120 |
Why?
| | Patient Readmission | 1 | 2019 | 609 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 2 | 2013 | 815 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2021 | 844 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 1361 | 0.120 |
Why?
| | Trauma Centers | 2 | 2014 | 329 | 0.110 |
Why?
| | Morbidity | 4 | 2021 | 278 | 0.110 |
Why?
| | Unnecessary Procedures | 1 | 2014 | 43 | 0.110 |
Why?
| | Abdomen | 1 | 2013 | 104 | 0.110 |
Why?
| | Radiation Dosage | 1 | 2014 | 139 | 0.110 |
Why?
| | Clinical Competence | 1 | 2019 | 912 | 0.110 |
Why?
| | Renal Insufficiency | 1 | 2013 | 137 | 0.100 |
Why?
| | Risk Factors | 5 | 2019 | 8697 | 0.100 |
Why?
| | Asia | 2 | 2021 | 53 | 0.090 |
Why?
| | Triage | 1 | 2012 | 192 | 0.090 |
Why?
| | Age Factors | 4 | 2022 | 2907 | 0.090 |
Why?
| | Carcinoma, Renal Cell | 1 | 2012 | 168 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1405 | 0.090 |
Why?
| | Europe | 2 | 2021 | 336 | 0.090 |
Why?
| | Kidney Transplantation | 2 | 2013 | 558 | 0.080 |
Why?
| | Graft Survival | 2 | 2009 | 480 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1180 | 0.080 |
Why?
| | Organ Preservation Solutions | 2 | 2006 | 42 | 0.080 |
Why?
| | Brain Injuries | 1 | 2014 | 451 | 0.080 |
Why?
| | Young Adult | 7 | 2022 | 10470 | 0.080 |
Why?
| | Laparotomy | 1 | 2008 | 96 | 0.080 |
Why?
| | Kidney Neoplasms | 1 | 2012 | 326 | 0.080 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2008 | 25 | 0.080 |
Why?
| | Biliary Tract Surgical Procedures | 1 | 2008 | 25 | 0.080 |
Why?
| | Gallbladder Neoplasms | 1 | 2007 | 11 | 0.080 |
Why?
| | Neoplasm Invasiveness | 3 | 2020 | 445 | 0.070 |
Why?
| | Intraoperative Care | 1 | 2007 | 36 | 0.070 |
Why?
| | Anus Neoplasms | 1 | 2007 | 24 | 0.070 |
Why?
| | Cholangitis, Sclerosing | 1 | 2008 | 74 | 0.070 |
Why?
| | Electrocoagulation | 1 | 2007 | 38 | 0.070 |
Why?
| | Hospital Mortality | 3 | 2019 | 779 | 0.070 |
Why?
| | Congenital Hypothyroidism | 1 | 1986 | 11 | 0.070 |
Why?
| | Ultrasonography, Interventional | 1 | 2007 | 125 | 0.070 |
Why?
| | Fluorouracil | 2 | 2022 | 151 | 0.070 |
Why?
| | Adolescent | 9 | 2022 | 17889 | 0.070 |
Why?
| | Mycophenolic Acid | 1 | 2006 | 81 | 0.060 |
Why?
| | Pandemics | 2 | 2023 | 1334 | 0.060 |
Why?
| | Wounds and Injuries | 1 | 2012 | 725 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2009 | 2578 | 0.060 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2019 | 182 | 0.060 |
Why?
| | Zygomycosis | 1 | 2003 | 6 | 0.060 |
Why?
| | Developmental Disabilities | 1 | 1986 | 240 | 0.060 |
Why?
| | alpha-Fetoproteins | 1 | 2023 | 32 | 0.060 |
Why?
| | Comorbidity | 2 | 2022 | 1473 | 0.060 |
Why?
| | Antibiotic Prophylaxis | 1 | 2004 | 96 | 0.050 |
Why?
| | Hepatocytes | 1 | 2004 | 197 | 0.050 |
Why?
| | Inflammation | 2 | 2023 | 2499 | 0.050 |
Why?
| | Appendicitis | 1 | 2004 | 108 | 0.050 |
Why?
| | Pneumonectomy | 1 | 2023 | 126 | 0.050 |
Why?
| | Biology | 1 | 2023 | 78 | 0.050 |
Why?
| | Capecitabine | 1 | 2022 | 46 | 0.050 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2007 | 577 | 0.050 |
Why?
| | CA-19-9 Antigen | 1 | 2022 | 13 | 0.050 |
Why?
| | Anesthesia, Intravenous | 1 | 2021 | 9 | 0.050 |
Why?
| | Surgical Wound Infection | 1 | 2004 | 250 | 0.050 |
Why?
| | Anesthetics, Intravenous | 1 | 2021 | 27 | 0.050 |
Why?
| | Liver | 2 | 2006 | 1690 | 0.050 |
Why?
| | Esophagogastric Junction | 1 | 2021 | 42 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2021 | 56 | 0.050 |
Why?
| | Models, Biological | 1 | 2008 | 1646 | 0.050 |
Why?
| | Medical Oncology | 1 | 2022 | 230 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2007 | 3022 | 0.050 |
Why?
| | Thoracoscopy | 1 | 2020 | 53 | 0.050 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2020 | 61 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2019 | 33 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 103 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2004 | 1093 | 0.040 |
Why?
| | Obesity | 1 | 2010 | 2517 | 0.040 |
Why?
| | Perioperative Period | 1 | 2017 | 49 | 0.040 |
Why?
| | Operative Time | 1 | 2017 | 109 | 0.040 |
Why?
| | Carcinoma, Lobular | 1 | 2017 | 44 | 0.040 |
Why?
| | ROC Curve | 2 | 2009 | 451 | 0.040 |
Why?
| | Occipital Bone | 1 | 2017 | 18 | 0.040 |
Why?
| | Parotid Gland | 1 | 2017 | 26 | 0.040 |
Why?
| | Gastric Emptying | 1 | 2017 | 40 | 0.040 |
Why?
| | Perioperative Care | 1 | 2018 | 126 | 0.030 |
Why?
| | Neck | 1 | 2017 | 84 | 0.030 |
Why?
| | Sex Factors | 1 | 2022 | 1736 | 0.030 |
Why?
| | Preoperative Care | 2 | 2008 | 318 | 0.030 |
Why?
| | Raffinose | 2 | 2006 | 20 | 0.030 |
Why?
| | Allopurinol | 2 | 2006 | 55 | 0.030 |
Why?
| | Consensus | 1 | 2017 | 532 | 0.030 |
Why?
| | Glucose | 1 | 2020 | 904 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 287 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 4435 | 0.030 |
Why?
| | Glutathione | 2 | 2006 | 303 | 0.030 |
Why?
| | Adenosine | 2 | 2006 | 203 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 724 | 0.030 |
Why?
| | Glasgow Coma Scale | 1 | 2014 | 144 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2017 | 497 | 0.030 |
Why?
| | Child | 6 | 2014 | 18488 | 0.030 |
Why?
| | Incidence | 1 | 2019 | 2335 | 0.030 |
Why?
| | Child, Preschool | 4 | 2014 | 9133 | 0.030 |
Why?
| | Disease Progression | 1 | 2020 | 2418 | 0.030 |
Why?
| | Diagnostic Tests, Routine | 1 | 2014 | 88 | 0.030 |
Why?
| | Radiation Injuries | 1 | 2014 | 127 | 0.030 |
Why?
| | Vital Signs | 1 | 2012 | 36 | 0.030 |
Why?
| | New South Wales | 1 | 2012 | 10 | 0.030 |
Why?
| | Baltimore | 1 | 2012 | 43 | 0.030 |
Why?
| | Italy | 1 | 2012 | 92 | 0.030 |
Why?
| | Hospital Costs | 1 | 2012 | 105 | 0.030 |
Why?
| | Pharmaceutical Preparations | 1 | 2013 | 169 | 0.020 |
Why?
| | Albuminuria | 1 | 1992 | 164 | 0.020 |
Why?
| | Biological Therapy | 1 | 2011 | 26 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 499 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 4665 | 0.020 |
Why?
| | Injury Severity Score | 1 | 2012 | 458 | 0.020 |
Why?
| | Lung | 1 | 2023 | 3672 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2013 | 605 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2014 | 5077 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1440 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 666 | 0.020 |
Why?
| | Carcinoembryonic Antigen | 1 | 2008 | 37 | 0.020 |
Why?
| | Infant | 3 | 2014 | 7979 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 83 | 0.020 |
Why?
| | Brazil | 1 | 2008 | 93 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1718 | 0.020 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2008 | 125 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4113 | 0.020 |
Why?
| | Radiopharmaceuticals | 1 | 2008 | 187 | 0.020 |
Why?
| | Cholecystectomy | 1 | 2007 | 45 | 0.020 |
Why?
| | Retreatment | 1 | 2007 | 70 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2008 | 284 | 0.020 |
Why?
| | Incidental Findings | 1 | 2007 | 76 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2007 | 105 | 0.020 |
Why?
| | Hepatitis B | 1 | 2007 | 53 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2007 | 183 | 0.020 |
Why?
| | Tablets, Enteric-Coated | 1 | 2006 | 4 | 0.020 |
Why?
| | Histidine | 1 | 2006 | 57 | 0.020 |
Why?
| | Overweight | 1 | 2010 | 469 | 0.020 |
Why?
| | Psychological Tests | 1 | 1986 | 123 | 0.020 |
Why?
| | Radiography | 1 | 2008 | 826 | 0.020 |
Why?
| | Insulin | 2 | 2006 | 2082 | 0.020 |
Why?
| | Graft Rejection | 1 | 2009 | 533 | 0.020 |
Why?
| | Tryptophan | 1 | 2006 | 136 | 0.020 |
Why?
| | Glutathione Disulfide | 1 | 2004 | 27 | 0.010 |
Why?
| | Hepatitis C | 1 | 2007 | 229 | 0.010 |
Why?
| | Gastrointestinal Diseases | 1 | 2006 | 184 | 0.010 |
Why?
| | Sulfamethoxypyridazine | 1 | 1983 | 1 | 0.010 |
Why?
| | Trimethoprim | 1 | 1983 | 6 | 0.010 |
Why?
| | Liver Function Tests | 1 | 2004 | 105 | 0.010 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 1983 | 13 | 0.010 |
Why?
| | Amphotericin B | 1 | 2003 | 32 | 0.010 |
Why?
| | Liver Diseases | 1 | 2006 | 263 | 0.010 |
Why?
| | Patient Selection | 1 | 2007 | 654 | 0.010 |
Why?
| | Antifungal Agents | 1 | 2003 | 133 | 0.010 |
Why?
| | Body Mass Index | 1 | 2010 | 1971 | 0.010 |
Why?
| | Cause of Death | 1 | 2004 | 368 | 0.010 |
Why?
| | Urinary Tract Infections | 1 | 1983 | 136 | 0.010 |
Why?
| | Immunocompromised Host | 1 | 2003 | 197 | 0.010 |
Why?
| | Reperfusion Injury | 1 | 2004 | 254 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 1992 | 1724 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1992 | 3254 | 0.010 |
Why?
| | Cholesterol | 1 | 1992 | 369 | 0.010 |
Why?
| | Blood Pressure | 1 | 1992 | 1537 | 0.000 |
Why?
| | Sulfamethoxazole | 1 | 1983 | 6 | 0.000 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1983 | 39 | 0.000 |
Why?
| | Escherichia coli Infections | 1 | 1983 | 102 | 0.000 |
Why?
| | Drug Combinations | 1 | 1983 | 289 | 0.000 |
Why?
| | Microbial Sensitivity Tests | 1 | 1983 | 299 | 0.000 |
Why?
| | Escherichia coli | 1 | 1983 | 730 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1983 | 941 | 0.000 |
Why?
|
|
Gleisner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|